Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cns Pharmaceuticals, Inc. (CNSP) since 2020 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Cns Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1729427.
Total stock buying since 2020: $458,583.
Total stock sales since 2020: $133,113.
Total stock option exercises since 2020: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 299,998 | $89,996 | 0 | $0 | 0 | $0 |
| 2023 | 57,523 | $69,014 | 75,000 | $85,999 | 1,771 | $0 |
| 2022 | 0 | $0 | 19,298 | $47,114 | 0 | $0 |
| 2021 | 9,500 | $9,893 | 0 | $0 | 0 | $0 |
| 2020 | 142,000 | $289,680 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-02 | 299,998 | $89,996 | 0 | $0 | 0 | $0 |
| 2023-08 | 29,750 | $39,126 | 0 | $0 | 0 | $0 |
| 2023-04 | 27,773 | $29,888 | 0 | $0 | 1,771 | $0 |
| 2023-03 | 0 | $0 | 75,000 | $85,999 | 0 | $0 |
| 2022-12 | 0 | $0 | 19,298 | $47,114 | 0 | $0 |
| 2021-12 | 5,000 | $4,700 | 0 | $0 | 0 | $0 |
| 2021-11 | 4,500 | $5,193 | 0 | $0 | 0 | $0 |
| 2020-08 | 142,000 | $289,680 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-02-01 | Gumulka Jerzy | Buy | 33,333 | .30 | 9,999 |
| 2024-02-01 | Evans Carl Anthony | Buy | 33,333 | .30 | 9,999 |
| 2024-02-01 | Downs Christopher (Chief Financial Officer) | Buy | 66,666 | .30 | 19,999 |
| 2024-02-01 | Climaco John M (Chief Executive Officer) | Buy | 166,666 | .30 | 49,999 |
| 2023-08-22 | Downs Christopher (Chief Financial Officer) | Buy | 27,000 | 1.27 | 34,182 |
| 2023-08-16 | Climaco John M (Chief Executive Officer) | Buy | 2,750 | 1.80 | 4,944 |
| 2023-04-28 | Downs Christopher (Chief Financial Officer) | Option Ex | 521 | .00 | 0 |
| 2023-04-28 | Climaco John M (Chief Executive Officer) | Option Ex | 1,250 | .00 | 0 |
| 2023-04-19 | Gumulka Jerzy | Buy | 2,500 | 1.70 | 4,250 |
| 2023-04-17 | Downs Christopher (Chief Financial Officer) | Buy | 3,100 | 3.20 | 9,920 |
| 2023-04-12 | Climaco John M (Chief Executive Officer) | Buy | 15,000 | .69 | 10,410 |
| 2023-04-10 | Gumulka Jerzy | Buy | 7,173 | .74 | 5,308 |
| 2023-03-28 | Priebe Waldemar | Sale | 10,000 | 1.04 | 10,400 |
| 2023-03-27 | Priebe Waldemar | Sale | 5,000 | 1.09 | 5,450 |
| 2023-03-24 | Priebe Waldemar | Sale | 5,000 | 1.08 | 5,400 |
| 2023-03-23 | Priebe Waldemar | Sale | 10,000 | 1.08 | 10,800 |
| 2023-03-22 | Priebe Waldemar | Sale | 5,000 | 1.08 | 5,400 |
| 2023-03-21 | Priebe Waldemar | Sale | 5,000 | 1.10 | 5,500 |
| 2023-03-20 | Priebe Waldemar | Sale | 5,000 | 1.08 | 5,400 |
| 2023-03-17 | Priebe Waldemar | Sale | 5,000 | 1.13 | 5,649 |
| 2023-03-16 | Priebe Waldemar | Sale | 5,000 | 1.24 | 6,200 |
| 2023-03-15 | Priebe Waldemar | Sale | 5,000 | 1.22 | 6,100 |
| 2023-03-14 | Priebe Waldemar | Sale | 5,000 | 1.35 | 6,750 |
| 2023-03-13 | Priebe Waldemar | Sale | 5,000 | 1.30 | 6,500 |
| 2023-03-10 | Priebe Waldemar | Sale | 5,000 | 1.29 | 6,450 |
| 2022-12-09 | Priebe Waldemar | Sale | 2,798 | 2.43 | 6,799 |
| 2022-12-08 | Priebe Waldemar | Sale | 5,500 | 2.40 | 13,200 |
| 2022-12-07 | Priebe Waldemar | Sale | 5,500 | 2.46 | 13,530 |
| 2022-12-06 | Priebe Waldemar | Sale | 5,500 | 2.47 | 13,585 |
| 2021-12-06 | Downs Christopher (Chief Financial Officer) | Buy | 5,000 | .94 | 4,700 |
| 2021-11-19 | Downs Christopher (Chief Financial Officer) | Buy | 4,500 | 1.15 | 5,193 |
| 2020-08-24 | Downs Christopher (Chief Financial Officer) | Buy | 142,000 | 2.04 | 289,680 |
Insider trading activities including stock purchases, stock sales, and option exercises of CNSP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Cns Pharmaceuticals, Inc. (symbol CNSP, CIK number 1729427) see the Securities and Exchange Commission (SEC) website.